Renagel

Hyperphosphataemia, Hemodialysis
Treatment
2 FDA approvals
14 Active Studies for Renagel

What is Renagel

SevelamerThe Generic name of this drug
Treatment SummarySevelamer is a medication used to reduce the levels of phosphate in the blood of people with chronic kidney disease. It is sold under the brand name Renagel and is used to prevent high phosphate levels, which can cause serious health problems.
Renagelis the brand name
image of different drug pills on a surface
Renagel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Renagel
Sevelamer
2006
81

Approved as Treatment by the FDA

Sevelamer, otherwise called Renagel, is approved by the FDA for 2 uses including Hyperphosphataemia and Hemodialysis .
Hyperphosphataemia
Helps manage Hyperphosphataemia
Hemodialysis
Helps manage Hemodialysis Treatment

Effectiveness

How Renagel Affects PatientsPeople with end-stage renal disease often have too much phosphorus in their blood, which can lead to calcium buildup in the body (called ectopic calcification). High levels of phosphorus can also cause the parathyroid hormone (PTH) levels to increase, which can cause a bone disease called osteitis fibrosa. To treat hyperphosphatemia, doctors may recommend reducing dietary intake of phosphate, taking drugs to block phosphate absorption, and undergoing dialysis. Sevelamer is a medication that can be taken with meals to reduce serum phosphorus levels. Studies have also shown that sevelamer can lower low-density lipoprotein
How Renagel works in the bodySevelamer stops the body from absorbing too much phosphate from food. This helps keep phosphate levels in the blood from becoming too high.

When to interrupt dosage

The measure of Renagel is contingent upon the determined condition. The measure of dosage fluctuates based on the method of delivery (e.g. Parenteral or Capsule) noted in the table underneath.
Condition
Dosage
Administration
Hyperphosphataemia
800.0 mg, , 400.0 mg, 403.0 mg, 1600.0 mg, 2400.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Powder, for suspension, Powder, for suspension - Oral, Parenteral, Tablet, film coated - Parenteral
Hemodialysis
800.0 mg, , 400.0 mg, 403.0 mg, 1600.0 mg, 2400.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Powder, for suspension, Powder, for suspension - Oral, Parenteral, Tablet, film coated - Parenteral

Warnings

There are 20 known major drug interactions with Renagel.
Common Renagel Drug Interactions
Drug Name
Risk Level
Description
Mycophenolic acid
Major
The serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.
Raloxifene
Major
Sevelamer can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.
Technetium Tc-99m oxidronate
Major
Sevelamer may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
(R)-warfarin
Minor
Sevelamer can cause a decrease in the absorption of (R)-warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.
(S)-Warfarin
Minor
Sevelamer can cause a decrease in the absorption of (S)-Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Renagel Toxicity & Overdose RiskSevelamer has been tested on healthy volunteers at doses of up to 14 grams per day for 8 days with no negative effects. Hemodialysis patients have been given up to 13 grams per day with no reported overdoses. Since sevelamer is not absorbed by the body, there is a low risk of developing systemic toxicity.
image of a doctor in a lab doing drug, clinical research

Renagel Novel Uses: Which Conditions Have a Clinical Trial Featuring Renagel?

11 active studies are currently evaluating the potential of Renagel in ameliorating Hyperphosphataemia.
Condition
Clinical Trials
Trial Phases
Hyperphosphataemia
0 Actively Recruiting
Hemodialysis
13 Actively Recruiting
Not Applicable, Phase 2

Renagel Reviews: What are patients saying about Renagel?

4.7Patient Review
11/21/2009
Renagel for High Amount of Phosphate in the Blood
I've been using Renagel for my dialysis treatments for the past 8 years and it has really helped to control my phosphorus levels. I typically take 5 tablets with each meal that contains protein. I haven't experienced any negative side effects and, although it is quite expensive, I would rather pay for this than risk long-term organ damage from something like Phoslo.
4Patient Review
12/27/2008
Renagel for Renal Osteodystrophy with Hyperphosphatemia
I had been taking Renagel to control my high phosphorus levels due to kidney failure, but it was very expensive and ineffective. When the doctors switched me to Phoslo, my phosphorus level dropped to an acceptable level.
3.7Patient Review
6/24/2011
Renagel for High Amount of Phosphate in the Blood
By my doctor's recommendation, I tried this treatment.
3.7Patient Review
6/7/2008
Renagel for Renal Osteodystrophy with Hyperphosphatemia
3.3Patient Review
5/7/2008
Renagel for High Amount of Phosphate in the Blood
2.7Patient Review
7/5/2009
Renagel for High Amount of Phosphate in the Blood
I find that taking Renagel 800mg constipates me and causes rectal bleeding. I take two tablets after each meal, which can be up to six per day. This results in bright red blood during bowel movements, which is sometimes accompanied by the feeling that I need to have a bowel movement.
2.7Patient Review
11/8/2009
Renagel for High Amount of Phosphate in the Blood
Renagel has been successful in lowering my phosphate levels; however, I am now frequently experiencing heartburn, especially in the morning. It's not a fun way to wake up!
2.3Patient Review
10/4/2009
Renagel for High Amount of Phosphate in the Blood
My husband has been taking this medication for approximately one month to help lower his phosphate level. However, he has frequently experienced nausea and vomiting, as well as changes in taste since starting the medication. He is requesting to go back on Phoslo.
2.3Patient Review
2/21/2011
Renagel for High Amount of Phosphate in the Blood
I'm not a fan of this medication because it seems to have caused constipation.
1.7Patient Review
12/18/2008
Renagel for Renal Osteodystrophy with Hyperphosphatemia
This treatment isn't always effective, but seems to work better when used in conjunction with Alumin Hydroxode liquid.
1Patient Review
2/15/2009
Renagel for High Amount of Phosphate in the Blood
This medication has been ineffective in controlling my itch, and if anything, it seems to be getting worse. I've already had to increase the dosage once at the recommendation of my doctor, but it doesn't seem to be helping.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about renagel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Renagel and Renvela?

"The next generation of Renagel, called Renvela, is just as effective in controlling serum phosphorus levels in patients with CKD, but has the added benefit of a carbonate buffer."

Answered by AI

What is Renagel used to treat?

"Sevelamer works by binding with phosphate in your intestine so that it is not absorbed into your blood.

Generic name: sevelamer HCL Sevelamer is used to lower high blood phosphorus (phosphate) levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Sevelamer works by binding with phosphate in your intestine so that it is not absorbed into your blood."

Answered by AI

Does Renagel cause constipation?

"If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

The following is a brief summary of the drug for the patient or caregiver from First DataBank. SIDE EFFECTS: Headache, diarrhea, stomach upset, nausea, vomiting, cough, gas, or constipation may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly."

Answered by AI

What is Renagel 800 mg used for?

"Renagel is a medication used to help adult kidney failure patients on dialysis to control the levels of phosphate in their blood."

Answered by AI

Clinical Trials for Renagel

Image of London Health Sciences Centre in London, Canada.

Wearable Ultrafiltration Device for Kidney Failure

18+
All Sexes
London, Canada
Kidney failure is common. In some people the ability of the kidneys to clean poisons out of the blood gets so low they need to be hooked up to a machine three times a week to do it for them. This is called dialysis. Unfortunately, although this treatment removes those waste products, people who need dialysis die much more often than people who don't need dialysis. Dialysis causes extreme stress on the body and leads to many organs being damaged. Removing fluid from the body quickly causes the equivalent of repeated little heart attacks or little strokes in the brain. Many patients struggle to tolerate having all the fluid that they have drunk since their last dialysis session removed- without unpleasant symptoms of dangerously low blood pressure (which makes the damage worse). Dialysis treatments can be done more slowly or more often, but that means having to spend a lot more time at the hospital and is difficult for the health system to be able to provide the extra treatment time. Could extra fluid be removed in between dialysis sessions? Up to now there has not been a way to effectively do this. Investigators have now designed and built an entirely new, very small and very simplified, device that can do part of what a dialysis machine does. It doesn't clean the blood or replace the need for conventional dialysis sessions, but it can provide additional and gentle removal of fluid which wasn't able to be taken off during a standard treatment session. If this study is successful, it will be the first time that a wearable device has been successfully built and used to take off extra fluid when dialysis patients are not in the hospital. The ability to do this opens up the possibility of, 1) helping to treat patients (both making people feel better and live longer) who can't tolerate getting off all the fluid in the short 3-4 hours they are on the dialysis machine in the hospital, and 2) helping patients who feel OK having the fluid taken off but are silently being subjected to damage to their organs due to the rapid removal, have reduced damage.
Waitlist Available
Has No Placebo
London Health Sciences CentreDr. Christopher McIntyre, MBBS DM
Image of DCI Desert Dialysis in Tucson, United States.

"Move More" Exercise Program for Hemodialysis Patients

18+
All Sexes
Tucson, AZ
The goal of this clinical trial is to compare the efficacy of a standard intradialytic exercise program (control group) to an individualized, patient-centered, "Move-More" physical activity intervention (intervention group) in hemodialysis (HD) patients. Exercise programs often fail to yield robust benefits for many HD patients, in part because the type and volume of exercise prescribed is inappropriate for a variety of reasons, and the benefits from these studies are often disappointing, as they are characterized by poor adherence, high dropout rates, and modest effects on physical function, body composition, cardiovascular disease risk, and other outcomes related to quality of life (QOL). To address this, the investigators have designed a novel physical activity intervention "Move More" that is designed to overcome many of the barriers to increasing physical activity in this population. This study aims to compare the efficacy of a standard intradialytic exercise program (control group) to an individualized, patient-centered, "Move-More" physical activity intervention (intervention group) in HD patients. The investigators primary hypothesis is that patients randomized to the Move More intervention will increase their physical activity levels more than those in the intradialytic exercise group. The main question it aims to answer is: • Does "Move More" increase the physical activity levels (minutes) measured through weekly minutes of physical activity and the LoPAQ questionnaire more than those in the standard intradialytic exercise program? For secondary outcomes this study aims to answer the following: * Does "Move More" improve the physical function of hemodialysis patients assessed by the short physical performance battery (SPBB) more than those in the standard intradialytic exercise program? * Does "Move More" decrease fatigue assess by the SONG-HD survey more than those in the standard intradialytic exercise program? * Does "Move More" decrease symptoms of depression assessed by PROMIS Depression Short Form 8a more than those in the standard intradialytic exercise program? * Does "Move More" increase the amount of exercise measured through a point system more than those in the standard intradialytic exercise program? * Does "Move More" improve blood pressure (BP) more than those in the standard intradialytic exercise program?
Recruiting
Has No Placebo
DCI Desert DialysisKenneth R Wilud, PhD
Have you considered Renagel clinical trials? We made a collection of clinical trials featuring Renagel, we think they might fit your search criteria.Go to Trials
Image of Fayette Surgical Associates in Lexington, United States.

InnAVasc Graft Implant for Kidney Failure

18 - 90
All Sexes
Lexington, KY
The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are: Primary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months. Primary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months. Participants will be asked to sign an informed consent form. Once enrolled, they will be assessed to receive the study graft implant and asked to participate in periodic follow-up visits and assessments through 2 years following implant.
Recruiting
Has No Placebo
Fayette Surgical Associates (+14 Sites)John Ross, MDInnAVasc Medical, Inc.
Have you considered Renagel clinical trials? We made a collection of clinical trials featuring Renagel, we think they might fit your search criteria.Go to Trials
Image of London Health Sciences Centre in London, Canada.

Higher vs. Lower Hemodialysate Magnesium for Kidney Failure

18+
All Sexes
London, Canada
Many patients on hemodialysis have low levels of magnesium. Magnesium is needed to keep the heart, kidneys, and other organs working properly. Patients with low serum magnesium concentration have a higher risk of death, heart issues, muscle cramps and fractures. There are several reasons why patients on dialysis have low levels of magnesium-these include poor diet, medication interference, and the dialysis procedure itself, which leaches small amounts of magnesium from the blood during each treatment. One way to make sure that patients on dialysis are getting enough magnesium is to increase its concentration in the dialysate. The investigator would like to do a randomized controlled trial to determine the effect of increasing the concentration of magnesium in the dialysate on the risk of people on dialysis dying or being admitted to the hospital due to heart issues. The investigator thinks increasing the magnesium in the dialysate will help patients live longer, have fewer hospitalisations related to heart disease and patients may also experience less cramping associated with dialysis. This simple adjustment to the dialysis procedure can be done at little cost and may even reduce overall healthcare costs. If the investigator can show that increasing magnesium in the dialysate improves patients' health, then it could become the standard of care for all patients on dialysis.
Waitlist Available
Has No Placebo
London Health Sciences CentreAmit X Garg, PhD, MDICES
Image of North Florida/South Georgia Veterans Health System, Gainesville, FL in Gainesville, United States.

Comprehensive Pre-ESKD Education for Chronic Kidney Disease

18+
All Sexes
Gainesville, FL
This study is intended to correct an important systemic deficit in the care of chronic kidney disease (CKD), VHA's fourth most common healthcare condition with high mortality and healthcare burden. Currently, many Veterans with CKD have poor awareness of their condition. This leads to suboptimal care. The investigators anticipate that the proposed comprehensive pre-end stage renal disease (ESRD) education (CPE) will enhance Veterans' CKD knowledge and their confidence in making an informed selection of an appropriate dialysis modality, and lead to an increase in the use of home dialysis (HoD) - an evidence-based, yet underutilized dialysis modality. Further, this study will allow us to examine whether such Veteran-informed dialysis choice can improve Veteran and health services outcomes. If successful, this study may deliver a ready to roll-out strategy to meet the CKD care needs of the Veterans and reduce VHA healthcare costs.
Waitlist Available
Has No Placebo
North Florida/South Georgia Veterans Health System, Gainesville, FLAshutosh M. Shukla, MD MBBS
Image of University Hospital in London, Canada.

Cardiac Monitoring System for Arrhythmia in Hemodialysis Patients

18+
All Sexes
London, Canada
Patients receiving dialysis for kidney failure suffer from very high rates of sudden cardiac death due to abnormal heart rhythms and perfusion defects associated with HD treatment. It has previously been recognized that patients suffer heart injury during the dialysis procedure which may be an important factor for investigation. The study uses a simple implantable device that can monitor heart rhythms over time to gather information on the type of abnormal rhythms that occur in dialysis patients. This information will be combined with ultrasound and x-ray scans of the heart that will also be collected. The goal is to understand the relationship between the abnormal rhythms and injury to the heart during dialysis and what causes these injuries. The information gathered in this study will be used to compare the accuracy of an in house personalized computational model to predict potential cardiac injuries when patients undergo HD treatment.
Waitlist Available
Has No Placebo
University Hospital (+1 Sites)Christopher W McIntyre, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security